Literature DB >> 18427570

Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.

F R Schroeck1, L Sun, S J Freedland, J Jayachandran, C N Robertson, J W Moul.   

Abstract

We hypothesized that factors beyond pathological stage, grade, PSA and margin status would be important predictors of biochemical recurrence (BCR) after radical prostatectomy (RP). A cohort of 3194 patients who underwent RP between 1988 and 2007 and who had neither neoadjuvant therapy nor postoperative adjuvant hormonal therapy was retrieved from the Duke Prostate Center database. Age, prostate-specific antigen (PSA), pathological Gleason score (pG), lymph node status, seminal vesicle invasion (SVI), extracapsular extension (ECE), positive surgical margin (PSM) status, year of surgery, race, adjuvant radiation therapy (XRT), percent tumor involvement in the RP specimen and prostate weight were evaluated as possible predictors of BCR in multivariate Cox regression analysis. BCR was defined as a PSA of 0.2 ng ml(-1) or higher at least 30 days after surgery. A nomogram was developed from the Cox model. Predictive accuracy was obtained by calculating bias-corrected Harrell's c and by bootstrap calibration. In multivariate analysis, PSA (hazard ratio 1.39 (95% confidence interval 1.29-1.51)), ECE (1.22 (1.04-1.44)), pG score (1.38 (1.14-1.68), 2.23 (1.76-2.84), 2.69 (2.12-3.40) for pG 3+4, 4+3, >7, respectively), SVI (1.72 (1.40-2.12)), PSM (2.05 (1.73-2.42)), year of surgery (0.65 (0.54-0.77)), African-American race (1.37 (1.13-1.66)), adjuvant XRT (0.19 (0.11-0.34)) and prostate weight (0.83 (0.76-0.92)) were identified as independent predictors of BCR (P< or =0.018 for all factors). Predictive accuracy of the nomogram was 0.75. Race and prostate weight were independent predictors for BCR after RP. By incorporating these variables, we developed a nomogram, which provides a highly accurate means for estimating risk of BCR after RP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18427570     DOI: 10.1038/pcan.2008.18

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  15 in total

1.  Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group.

Authors:  Anna E Teeter; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  Urology       Date:  2013-07       Impact factor: 2.649

2.  Predicting Prostate Cancer Recurrence After Radical Prostatectomy.

Authors:  Abra Jeffers; Vanessa Sochat; Michael W Kattan; Changhong Yu; Erin Melcon; Kosj Yamoah; Timothy R Rebbeck; Alice S Whittemore
Journal:  Prostate       Date:  2016-10-24       Impact factor: 4.104

3.  Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.

Authors:  Stephen J Freedland; Adriana C Vidal; Lauren E Howard; Martha K Terris; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; William J Aronson
Journal:  Cancer       Date:  2017-06-27       Impact factor: 6.860

4.  Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.

Authors:  Daniel M Moreira; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Leon L Sun; Judd W Moul; Stephen J Freedland
Journal:  Int J Urol       Date:  2010-09-30       Impact factor: 3.369

5.  Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy.

Authors:  Eric J Whitman; Mark Pomerantz; Yongmei Chen; Michael M Chamberlin; Bungo Furusato; Chunling Gao; Amina Ali; Lakshmi Ravindranath; Albert Dobi; Isabell A Sesterhenn; Isabell A Sestrehenn; David G McLeod; Shiv Srivastava; Matthew Freedman; Gyorgy Petrovics
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

6.  Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?

Authors:  Matthew A Uhlman; Leon Sun; Danielle A Stackhouse; Arthur A Caire; Thomas J Polascik; Cary N Robertson; John Madden; Robin Vollmer; David M Albala; Judd W Moul
Journal:  Urology       Date:  2009-10-12       Impact factor: 2.649

7.  The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.

Authors:  D M Moreira; J C Presti; W J Aronson; M K Terris; C J Kane; C L Amling; L L Sun; J W Moul; S J Freedland
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-11-17       Impact factor: 5.554

8.  Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy.

Authors:  Florian R Schroeck; Michael W Kattan; Judd W Moul; William J Aronson; Joseph C Presti; Martha K Terris; Christopher J Kane; Christopher L Amling; Leon Sun; Stephen J Freedland
Journal:  BJU Int       Date:  2009-11-13       Impact factor: 5.588

9.  Clinical Usefulness of Prostate and Tumor Volume Related Parameters following Radical Prostatectomy for Localized Prostate Cancer.

Authors:  Yujiro Ito; Kazuma Udo; Emily A Vertosick; Daniel D Sjoberg; Andrew J Vickers; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; S Joseph Sirintrapun; Satish K Tickoo; Peter T Scardino; James A Eastham; Victor E Reuter; Samson W Fine
Journal:  J Urol       Date:  2019-03       Impact factor: 7.450

10.  Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?

Authors:  Florian R Schroeck; William J Aronson; Joseph C Presti; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland
Journal:  BJU Int       Date:  2008-11-18       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.